Pharmacy Grand Rounds
IDK about IBD: Tune in to Learn About Medical Treatment of Inflammatory Bowel Disease

• ACPE Universal Activity Number (UAN): JA0000238-0000-20-028-L01-P
• Session Type: Knowledge-based
• CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following: 
  • AAPA Category 1 CME Credits
  • ACPE
  • AMA PRA Category 1 Credits™
  • ANCC

• Session Fee: Free for Mayo Clinic staff

SESSION LOCATIONS

Live Session: (11:00am - 11:45am CST) 

Until further notice, learners must watch Pharmacy Grand Rounds live via the web by going to the Video Exchange and selecting “Pharmacy Grand Rounds” in the “Streaming Now” section.

Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date

COURSE DESCRIPTION
Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease, affects an estimated 3 million adults in the United States and is increasing in incidence and prevalence. In order to improve patient outcomes, pharmacist involvement in providing care to patients with IBD is essential. Pharmacists may be involved in using shared decision making to select and educate patients on the use of available conventional and biologic agents and applying strategies to optimize medical treatment. Therefore, continuing education is vital to help pharmacists become well-informed on the latest evidence-based management approaches. This presentation will review the current IBD guidelines, biologic agents, and combination therapies and will address other identified educational gaps including preventive health and IBD in pregnancy.

At the conclusion of this knowledge-based CE session, participants should be able to:

• Describe factors contributing to the selection of medical therapy and health maintenance in Inflammatory Bowel Disease (IBD)
• Recall resources available to guide clinical decision making regarding medical treatment of IBD
• Identify various roles of pharmacists in the care of patients with IBD

Session Announcement..pdf

Presentation Slides.pdf

FACULTY INFORMATION

Carey L. Jones, PharmD, BCACP, BCPS
Specialty Pharmacist
Mayo Clinic Specialty Pharmacy - Rochester, MN

Carey received a Doctor of Pharmacy degree from Drake University and subsequently worked as a clinical pharmacy specialist at the University of Iowa Hospitals and Clinics (UIHC) from 2014 to 2019. In this role, Dr. Jones had a clinical practice within the Digestive Health Center that focused on Inflammatory Bowel Disease.  She has also co-authored multiple publications on GERD and IBD. In 2019, Dr. Jones started working at Mayo Clinic Specialty Pharmacy as a specialty pharmacist. 

Michelle D. Becker, PharmD
Clinical Pharmacist
Mayo Clinic Inflammatory Bowel Disease Clinic - Rochester, MN

Michelle earned a Doctor of Pharmacy degree with a concentration in Public and Global Health from Drake University, with subsequent completion of a PGY1 pharmacy residency at Hennepin Healthcare. Upon joining Mayo Clinic, Dr. Becker established a Medication Management Services Pharmacist position for the Inflammatory Bowel Disease Clinic at Mayo Clinic - Rochester. Dr. Becker has developed a robust clinical practice involving direct care of patients, especially when starting on new biologic therapy, and indirectly by supporting the clinical team.
 

DISCLOSURE STATEMENTS
As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

• Carey L. Jones, PharmD, BCACP, BCPS
  • Declares no financial relationship(s) pertinent to this session
  • Declares off-label use of devices and medications will be discussed during this presentation, including:
    • Azathioprine
    • Mercaptopurine
    • Methotrexate
• Michelle D. Becker, PharmD
  • Declares no financial relationship(s) pertinent to this session
  • Declares off-label use of devices and medications will be discussed during this presentation, including:
    • Azathioprine
    • Mercaptopurine
    • Methotrexate

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session.  Members include:

• Brenda Amaris
• Mary Ellen Cordes, MS, APRN, CNC, NE-BC
• Jennifer Elmer, DNP, APRM, CCNS, FCCM
• Michael Huckabee, MPAS, PA-C, PhD
• Wayne (Nick) Nicholson, MD, PharmD, BCPS
• Garrett Schramm, PharmD, BCPS
• Lee Skrupky, PharmD, BCPS